Cargando…

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

BACKGROUND AND OBJECTIVES: To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings. METHODS: Safety analyses are based on inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hauser, Stephen L., Kappos, Ludwig, Montalban, Xavier, Craveiro, Licinio, Chognot, Cathy, Hughes, Richard, Koendgen, Harold, Pasquarelli, Noemi, Pradhan, Ashish, Prajapati, Kalpesh, Wolinsky, Jerry S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548959/ https://www.ncbi.nlm.nih.gov/pubmed/34475123 http://dx.doi.org/10.1212/WNL.0000000000012700

Ejemplares similares

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
por: Arnold, Douglas L, et al.
Publicado: (2022)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
por: Wolinsky, Jerry S, et al.
Publicado: (2020)

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
por: Bar-Or, Amit, et al.
Publicado: (2023)

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
por: Gibiansky, Ekaterina, et al.
Publicado: (2020)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
por: Fox, Edward J, et al.
Publicado: (2018)

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
por: Weinstock-Guttman, Bianca, et al.
Publicado: (2021)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis
por: Algahtani, Hussein, et al.
Publicado: (2023)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
por: Montalban, Xavier, et al.
Publicado: (2023)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
por: Klumpp, Annika, et al.
Publicado: (2022)

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
por: Garcia, Alexandra, et al.
Publicado: (2023)

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
por: Martins, Paulo, et al.
Publicado: (2022)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging
por: Kolind, Shannon, et al.
Publicado: (2023)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study
por: Miller, Aaron E., et al.
Publicado: (2014)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_aqmkj00kr7du06q30j9d351413